Pemazyre
Pemazyre ingredients
| Active ingredient | Strength |
|---|---|
| Pemigatinib | 4.5 mg/1, 13.5 mg/1, 9 mg/1 |
What Pemazyre is used for
The FDA lists the approved uses on the official label (below). In the EU, pemigatinib is approved as Pemazyre for:
Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Pemazyre
- Generic name
- Pemigatinib
- Made by
- Incyte Corporation
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA213736
- On the US market since
- 2020
Official information
- Pemazyre prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Pemigatinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Pemazyre?
Pemazyre (Pemigatinib) is a cancer medicine made by Incyte Corporation, approved by the US FDA.
What are the ingredients of Pemazyre?
Pemazyre contains Pemigatinib (4.5 mg/1, 13.5 mg/1, 9 mg/1).
Is Pemazyre approved in Europe?
The same active substance is approved in the EU as Pemazyre.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA